Tuberous Sclerosis Complex (TSC) - Epidemiology Forecast to 2027

October 2018 | 69 pages | ID: T19D5760DAEEN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Tuberous Sclerosis Complex (TSC) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Tuberous Sclerosis Complex (TSC) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

GEOGRAPHY COVERED

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Tuberous Sclerosis Complex (TSC)

The Tuberous Sclerosis Complex (TSC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Tuberous Sclerosis Complex (TSC) are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Tuberous Sclerosis Complex (TSC) Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, De novo mutations prevalent cases and Familiar Prevalent Cases) scenario of Tuberous Sclerosis Complex (TSC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total prevalent population of Tuberous Sclerosis Complex (TSC) was found to be 101,399, in the year 2016.

REPORT SCOPE

• The report covers detailed overview of Tuberous Sclerosis Complex (TSC) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Tuberous Sclerosis Complex (TSC) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by (De novo mutations cases and Familiar Cases) in 7MM

KEY STRENGTHS

• 10 Year Forecast of Tuberous Sclerosis Complex (TSC)
• 7MM Coverage
• Total Prevalent Cases of TSC
• Prevalent Cases according to segmentation: De novo mutations and Familiar Cases

KEY ASSESSMENTS

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. DISEASE OVERVIEW: TUBEROUS SCLEROSIS COMPLEX (TSC)

2.1. Introduction
2.2. Clinical Manifestations of Tuberous Sclerosis Complex
2.3. Etiology
2.4. Risk Factors
2.5. Inheritance Pattern
2.6. Signs and Symptoms
2.7. Pathophysiology
  2.7.1. Tuberous Sclerosis Complex (TSC) Genotype Analysis
2.8. Diagnosis
  2.8.1. Differential Diagnosis
  2.8.2. Diagnostic Criteria
  2.8.3. Diagnostic Recommendations

3. EPIDEMIOLOGY AND PATIENT POPULATION

3.1. Key Findings
3.2. Population and Forecast Parameters

4. 7MM TOTAL PREVALENT PATIENT POPULATION OF TUBEROUS SCLEROSIS COMPLEX

5. COUNTRY WISE-EPIDEMIOLOGY OF TUBEROUS SCLEROSIS COMPLEX

5.1. United States
  5.1.1. Prevalent Population of Tuberous Sclerosis Complex in the United States
  5.1.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
  5.1.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
5.2. Germany
  5.2.1. Prevalent Population of Tuberous Sclerosis Complex in Germany
  5.2.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
  5.2.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
5.3. France
  5.3.1. Prevalent Population of Tuberous Sclerosis Complex in France
  5.3.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
  5.3.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
5.4. Italy
  5.4.1. Prevalent Population of Tuberous Sclerosis Complex in Italy
  5.4.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
  5.4.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
5.5. Spain
  5.5.1. Prevalent Population of Tuberous Sclerosis Complex in Spain
  5.5.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
  5.5.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
5.6. United Kingdom
  5.6.1. Prevalent Population of Tuberous Sclerosis Complex in the UK
  5.6.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
  5.6.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
5.7. Japan
  5.7.1. Prevalent Population of Tuberous Sclerosis Complex in Japan
  5.7.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
  5.7.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex

6. APPENDIX

6.1. Report Methodology

7. DELVEINSIGHT CAPABILITIES

8. DISCLAIMER

9. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1: Characteristics of TSC1 and TSC2 genes
Table 2: Genotype Analysis of TSC1 and TSC2 genes
Table 3: Mutational Analysis of TSC1 and TSC2 genes
Table 4: Molecular Genetic Testing Used in Tuberous Sclerosis Complex
Table 5: Surveillance Recommendations for Diagnosis of Tuberous Sclerosis Complex
Table 6: Tuberous Sclerosis Association Recommendations for Diagnosis of Tuberous Sclerosis Complex
Table 7: Prevalent Patient Population of Tuberous Sclerosis Complex in the 7MM (2016-2027)
Table 8: Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Table 9: Familiar Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Table 10: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Table 11: Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Table 12: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Table 13: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Table 14: Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Table 15: Familiar Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Table 16: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Table 17: Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Table 18: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Table 19: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Table 20: Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Table 21: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Table 22: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Table 23: Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Table 24: Familiar Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Table 25: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Table 26: Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Table 27: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Table 28: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)

List Of Figures

LIST OF FIGURES

Figure 1: Clinical Manifestations of Tuberous Sclerosis Complex
Figure 2: Risk Factors for Tuberous Sclerosis Complex
Figure 3: Inheritance Pattern of Tuberous Sclerosis Complex
Figure 4: Signs and Symptoms of Tuberous Sclerosis Complex
Figure 5: Pathophysiology of Tuberous Sclerosis Complex
Figure 6: Prevalent Patient Population of Tuberous Sclerosis Complex in the 7MM (2016-2027)
Figure 7: Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Figure 8: Familiar Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Figure 9: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Figure 10: Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Figure 11: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Figure 12: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Figure 13: Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Figure 14: Familiar Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Figure 15: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Figure 16: Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Figure 17: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Figure 18: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Figure 19: Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Figure 20: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Figure 21: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Figure 22: Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Figure 23: Familiar Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Figure 24: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Figure 25: Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Figure 26: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Figure 27: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)